Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.55 USD | +2.14% | +6.11% | +24.35% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 524M |
---|---|---|---|---|---|
Net income 2024 * | -79M | Net income 2025 * | -101M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-6.17
x | P/E ratio 2025 * |
-4.85
x | Employees | 59 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.7% |
Latest transcript on Astria Therapeutics, Inc.
1 day | +2.14% | ||
1 week | +6.11% | ||
Current month | +4.03% | ||
1 month | -17.24% | ||
3 months | -27.10% | ||
6 months | +93.32% | ||
Current year | +24.35% |
Managers | Title | Age | Since |
---|---|---|---|
Jill Milne
FOU | Founder | 56 | 08-06-25 |
Noah Clauser
DFI | Director of Finance/CFO | 51 | 11-03-31 |
Chief Tech/Sci/R&D Officer | - | 22-07-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ken Bate
CHM | Chairman | 73 | 13-12-31 |
Gregg Lapointe
BRD | Director/Board Member | 65 | 19-01-03 |
Director/Board Member | 75 | 16-04-04 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 2 M€ | -.--% | ||
0.00% | 34 M€ | +2.67% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 9.55 | +2.14% | 537,584 |
24-05-02 | 9.35 | -1.58% | 807,906 |
24-05-01 | 9.5 | +3.49% | 2,724,503 |
24-04-30 | 9.18 | +0.33% | 539,553 |
24-04-29 | 9.15 | +1.67% | 633,353 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.35% | 524M | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |
- Stock Market
- Equities
- ATXS Stock